SOLTF Stock Chart & Stats
$7.08
-$0.36(-5.98%)
At close: 4:00 PM EDT
$7.08
-$0.36(-5.98%)
Day’s Range― - ―
52-Week Range$4.65 - $8.78
Previous CloseN/A
Volume400.00
Average Volume (3M)144.00
Market Cap
$793.75M
Enterprise Value$127.12B
Total Cash (Recent Filing)$17.75B
Total Debt (Recent Filing)$54.41B
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Oct 30, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend Yield0.54%
Share Statistics
EPS (TTM)-86.36
Shares Outstanding92,615,360
10 Day Avg. Volume10
30 Day Avg. Volume144
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.22
Price to Sales (P/S)2.52
P/FCF Ratio-23.96
Enterprise Value/Market Cap160.15
Enterprise Value/Revenue3.80
Enterprise Value/Gross Profit5.00
Enterprise Value/Ebitda57.62
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.3
Revenue Forecast (FY)$256.86M
Bulls Say, Bears Say
Bulls Say
Revenue And Profit InflectionThe return to operating profitability alongside 25% revenue growth indicates improving operating leverage and stronger execution. If this performance is sustained, it can support reinvestment in the pipeline, reduce reliance on external funding, and improve the durability of earnings over the next several quarters.
Commercial Product MomentumGrowth from marketed products gives Sosei a more tangible commercial foundation than discovery programs alone. Rising PIVLAZ and QUVIVIQ sales can diversify revenue toward product economics, strengthen market validation, and create a base for future launches and milestone opportunities.
Validated GPCR PlatformThe GPCR platform has produced repeated partner milestones and substantial headline economics, providing external validation of Sosei’s discovery capabilities. Continued partnering can extend the pipeline, share development costs, and create multiple future milestone and royalty opportunities without requiring full commercialization funding.
Bears Say
Persistent Losses And Volatile RevenueRecent losses and the sharp TTM revenue contraction show that the business has not yet established consistently durable earnings. Strong gross margins have not prevented operating deficits, so future profitability remains sensitive to revenue timing, development spending, and the success of commercial and partnered programs.
Lumpy Milestone DependenceMilestone-driven revenue can create substantial swings between reporting periods because payments depend on discrete partner and development events. This makes operating profit less predictable, complicates resource planning, and increases the risk that a delayed milestone temporarily weakens cash generation or reported earnings.
Reliance On Partners For Pipeline ProgressSosei’s decision not to self-fund global Phase II leaves advancement of important clinical assets dependent on securing suitable partners. Delayed or unfavorable licensing could postpone development, reduce near-term value realization, and limit the company’s control over clinical timelines and investment priorities.
Sosei Group News
SOLTF FAQ
What was Sosei Group Corporation’s price range in the past 12 months?
Sosei Group Corporation lowest stock price was $4.65 and its highest was $8.78 in the past 12 months.
What is Sosei Group Corporation’s market cap?
Sosei Group Corporation’s market cap is $793.75M.
When is Sosei Group Corporation’s upcoming earnings report date?
Sosei Group Corporation’s upcoming earnings report date is Oct 30, 2026 which is in 4 days.
How were Sosei Group Corporation’s earnings last quarter?
Sosei Group Corporation released its earnings results on Aug 07, 2026. The company reported -$0.015 earnings per share for the quarter, beating the consensus estimate of -$0.022 by $0.008.
Is Sosei Group Corporation overvalued?
According to Wall Street analysts Sosei Group Corporation’s price is currently Overvalued.
Does Sosei Group Corporation pay dividends?
Sosei Group Corporation pays a Notavailable dividend of $0.068 which represents an annual dividend yield of 0.54%. See more information on Sosei Group Corporation dividends here
What is Sosei Group Corporation’s EPS estimate?
Sosei Group Corporation’s EPS estimate is <0.01.
How many shares outstanding does Sosei Group Corporation have?
Sosei Group Corporation has 92,615,360 shares outstanding.
What happened to Sosei Group Corporation’s price movement after its last earnings report?
Sosei Group Corporation reported an EPS of -$0.015 in its last earnings report, beating expectations of -$0.022. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sosei Group Corporation?
Currently, no hedge funds are holding shares in SOLTF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sosei Group Corporation
Nxera Pharma Co., Ltd., established in Tokyo, Japan, in 1990, is a biopharmaceutical enterprise focused on the discovery, development, and commercialization of pharmaceutical solutions. The company's operations extend across multiple international markets, including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Its array of commercially available products encompasses respiratory treatments like Ultibro/Breezhaler and Seebri/Breezhaler for chronic obstructive pulmonary disease, as well as Enerzair and Breezhaler to manage asthma. Other marketed therapeutics include ORAVI, a unique formulation addressing oropharyngeal candidiasis, and PIVLAZ, prescribed for cerebral vasospasm. The firm boasts a robust pipeline of investigational medicines, featuring HTL0039732 for immuno-oncology, HTL0048149 for schizophrenia, Daridorexant targeting insomnia, and HTL0016878 for both schizophrenia and other neuropsychiatric conditions. Additional compounds under development include PF-07081532 for Type 2 diabetes mellitus and obesity, PF-07054894 for inflammatory bowel disease, PF-07258669 for anorexia, and PF-06954522 for metabolic disorders. The pipeline also contains NBI-1117569 for various neurological diseases and NBI-1117570 for central nervous system ailments. Furthermore, Nxera Pharma is advancing a GPR35 agonist in the preclinical stage for inflammatory bowel disease and other gastrointestinal conditions, alongside other early-stage drug candidates. The company maintains significant strategic collaborations with industry leaders such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily.
SOLTF Company Deck
SOLTF Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum: double-digit revenue growth, a move from IFRS loss to profit, substantial milestone receipts, clear product-level growth (notably PIVLAZ and QUVIVIQ), clinical and commercial validations (vamorolone data and Centessa/Lilly transaction), and an ambitious AI/GPCR discovery strategy with concrete efficiency targets. The principal risks emphasized were milestone revenue lumpiness, dependence on out-licensing/partners to advance key clinical assets, inventory-driven variability for partner-sold products, and execution/competitive risk for discovery programs. Overall, the positives — sustained revenue growth, return to profitability, multiple partner milestones, and concrete platform and pipeline roadmaps — materially outweigh the highlighted risks, which are primarily execution- and timing-related rather than reflective of deteriorating operating performance.View all SOLTF earnings summariesTechnical Analysis
Peptidream
―
SanBio Co
―
Oncolys BioPharma, Inc.
―
―
Japan Tissue Engineering Co., Ltd.
―
Ownership Overview
―
Insiders
3.10% Mutual Funds
― Other Institutional Investors
93.61% Public Companies and
Individual Investors